stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) EV/FCF
As of 5 November 2026, Arcus Biosciences, Inc. (RCUS) trades at a EV/FCF of −3.7×. Over the past ten years it has ranged from −16.3× (May 2020) to 143× (September 2021); the current reading is higher than 28% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −3.5× | — |
| FY2024 | −2.3× | — |
| FY2023 | −2.5× | — |
| FY2022 | 1.3× | — |
| FY2021 | −8.6× | — |
| FY2020 | 6.6× | — |
| FY2019 | −3.4× | — |
| FY2018 | −2.5× | — |
| FY2017 | 4.7× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −5.9× | — |
| Jun 2026 | −6.9× | — |
| Mar 2026 | −4.1× | — |
| Dec 2025 | −3.5× | — |
| 33 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MBX MBX Biosciences, Inc. compare | −22.3× |
| NAMS NewAmsterdam Pharma Company N.V. compare | −11.4× |
| XNCR Xencor, Inc. compare | −10.8× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −10.5× |
| PHVS Pharvaris N.V. compare | −10.5× |
| IDYA IDEAYA Biosciences, Inc. compare | −6.7× |
| BEAM Beam Therapeutics Inc. compare | −4.5× |
| RXRX Recursion Pharmaceuticals, Inc. compare | −4.3× |
| RCUS Arcus Biosciences, Inc. | −3.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement